Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.

Item

http://www.wikidata.org/entity/Q38007893

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Effect of Angiotensin-converti ...... in atherosclerosis prevention.

@en

type

Item

label

Effect of Angiotensin-converti ...... in atherosclerosis prevention.

@en

prefLabel

Effect of Angiotensin-converti ...... in atherosclerosis prevention.

@en

P1476

Effect of Angiotensin-converti ...... in atherosclerosis prevention.

@en

P2093

Gary S Francis

http://www.w3.org/2001/XMLSchema#string

Maria M Patarroyo Aponte

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.

High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

P2888

s11886-012-0275-9

P304

433-442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-012-0275-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1037590132

http://www.w3.org/2001/XMLSchema#string

P698

22562592

http://www.w3.org/2001/XMLSchema#string